Form 4: Castle Biosciences Director Daniel Bradbury Sells Shares Under 10b5-1 Plan

Director Daniel Bradbury of Castle Biosciences sold shares of common stock on December 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Bradbury, a director at Castle Biosciences, sold shares of the company's common stock on December 3, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• The transactions involved multiple sales at weighted average prices of $30.951 and $31.32.
• The shares were sold both directly and indirectly through various entities including BioBrit, LLC, and irrevocable descendant's trusts.
• A total of 8,767 shares were sold directly, and the remaining shares were sold indirectly through trusts and an LLC.

Sentiment

Score: 5

Explanation: The document is a routine filing of insider trading activity under a pre-arranged plan, which is neither positive nor negative in itself.

Risks

• Sales by insiders, even under a 10b5-1 plan, can sometimes be perceived negatively by the market.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by regulators and investors.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice for corporate insiders to avoid accusations of trading on non-public information.
• Many directors and officers of publicly traded companies use similar plans to manage their personal finances and comply with securities regulations.
• The volume of shares sold is not unusual for a director's transactions, but the market reaction can vary based on overall sentiment and company performance.

Stakeholder Impact

• The sales may have a minor impact on shareholder sentiment, but the pre-arranged nature of the transactions should mitigate any significant negative reaction.

Key Dates

Keywords

insider trading, Form 4, 10b5-1 plan, stock sale, Daniel Bradbury, Castle Biosciences, CSTL, director